Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

STAGE IIIA - Breast Carcinoma
 
 
STAGE I I I A - BREAST CARCINOMA
THERAPEUTIC OPTIONS
 
BREAST CARCINOMA STAGE III A (Locally Advanced)
TMN Classification

T0-3 N2M0

T3N1M0
Cell Type All
Description
Tumor Size Greater than 5 cm
Lymph Node Metastasis (Non fixed) or

Tunor of any size with fixed, cancerous lymph nodes
  • LOCAL/SURGICAL MANAGEMENT
 
Surgical Therapeutic Option : Modified Radical Mastectomy or Radical Mastectomy
Indication Operable Stage III A Carcinoma with mobile axillary lymph nodes
 
Surgical Therapeutic Option : Incisional Biopsy (Systemic Chemo and Hormonal Rx) with delayed Mastectomy or Lumpectomy with Axillary Dissection or Radical Mastectomy
Indication Non- Operable Stage III A Carcinoma - Neoadjuvant Chemotherapy used to shrink the tumor and convert it from non-resectable to resectable.
Key DATA ER-PR status on the original Incisional Biopsy
 
RadioTherapeutic Option : Post-operative External Beam Radiation to chest wall
Indication Should be considered / High risk for local recurrence
Note An additional boost is indicated for close margins.
  • SYSTEMIC TREATMENT: CHEMOTHERAPEUTIC & HORMONAL PROTOCOLS
   
RECOMMENDATION FOR STAGE IIIA

LYMPH NODES POSITIVE - ER/PR POSITIVE OR NEGATIVE
TMN Classification T0-3N2M0 or T3N1M0
Description Tumor Size Greater than 5 cm with non fixed , cancerous lymph nodes

or

Tumor of any size with fixed, cancerous lymph nodes
Recommendation CHEMOTHERAPY RECOMMENDED - HORMONAL THERAPY RECOMMENDED FOR ER/PR POSITIVE PATIENTS
RECOMMENDED CHEMOTHERAPEUTIC PROTOCOLS
CLICK ON EACH PROTOCOL
FOR DETAILED INFORMATION
 ADRIAMYCIN

CYTOXAN

& TAMOXIFEN

aka: AC-T

 CYTOXAN

METHOTREXATE

5FU

& TAMOXIFEN

aka: CMF-T

 ORAL CYTOXAN

METHOTREXATE

5FU

& TAMOXIFEN

aka: Classic CMF-T

 5FU

ADRIAMYCIN

CYTOXAN

& TAMOXIFEN

aka: FAC-T
All patients with large tumors should be considered for neoadjuvant treatment. If eligible, patients should be treated with a research protocol.
 
 

Copyright 1997 - TransMed Network